Keyue Pharmaceuticals will report the latest preclinical data of its lead project KP104 at the 18th European Conference on Complement and Human Disease

Oral presentation at the congress on the favorable pharmacokinetic and pharmacodynamic properties of intravenous and subcutaneous administration of KP104 in relevant animal models, supporting further development as a potent inhibitor of complement replacement and terminal dual pathways

Conference posters demonstrate synergistic effects of selective inhibition of the alternative and terminal pathways of complement in the treatment of complement-mediated diseases, including data from a new mouse model of C3 glomerulopathy (C3G)

CAMBRIDGE, Mass.

The conference will be held in Bern, Switzerland from 26 to 29 August

The complement system is a complex protein pathway and an important part of innate immunity

"Based on intellectual property licensed and developed by the University of Pennsylvania, Keyue's lead product, KP104, is designed to overcome the inherent pharmacokinetic and pharmacodynamic challenges of developing complement medicines

Ke Yue Medicine has completed a Phase 1 first-in-human (FIH) study evaluating KP104, which achieved a clinical proof-of-mechanism (POM), and is initiating a Phase 2 clinical proof-of-concept (POC) trial across multiple indications

Introduction to oral presentations

Title: Pharmacokinetics/Pharmacodynamics of KP104, a Bifunctional Antibody Fusion Protein Complement Inhibitor, in C5/FCRN Humanized Transgenic Mice and Cynomolgus Monkeys

Authors: Jay Ma1, Xiang Gao1, Takashi Miwa2, Damodar Gullipalli2, Sayaka Sato2, Wen-Chao Song2, Xihua Zhu3, Jianjun Zhang3, Chaomei He1, Helen Fu1, Richard Lee1, Frederick Beddingfield1,4, Wenru Song1, Ping Tsui*,1

Abstract number: 126

Session Topic: Scientific Session IV: Therapeutics

Conference Date and Time: August 28, 2022 9:15-9:30 EST

Executive Summary and Background: The results of this study demonstrate the optimal pharmacological characterization of KP104 in human C5 transgenic mice and non-human primates (NHPs), supporting its further development as a potent drug suitable for intravenous and subcutaneous administration.

1 Keyue Medicine, Cambridge, MA, 2 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3 Keyue Medicine, Suzhou, China, 4 Department of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, *corresponding author

Introduction to posters

Title: Design and Characterization of KP104: An Anti-C5 mAb and FH1-5 Bifunctional Fusion Protein Synergistically Inhibits Complement Alternative and Terminal Pathways

Authors: Takashi Miwa1, Damodar Gullipalli1, Sayaka Sato1, Madhu Golla1, Xihua Zhu2, Jianjun Zhang2, Dongqiong Fei2, Ping Tsui3, Fengkui Zhang4, Wen-Chao Song1

Poster No.

Conference Topic: Poster Browsing Conference 2

Conference Date and Time: August 28, 11:45-13:30 EST

Poster abstract and background: The poster describes the design and preliminary characterization of KP104

1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, 2 Ke Yue Medicine, Suzhou, China, 3 Ke Yue Medicine, Cambridge, MA, USA, 4 Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China

Title: Therapeutic effect of anti-C5 mAb/FH1-5 bifunctional fusion protein in a mouse model of rapidly progressive lethal C3 nephropathy

Authors: Sayaka Sato1, Takashi Miwa1, Damodar Gullipalli1, Lin Zhou1, Jianjun Zhang2, Xiaoxia Hu2, Bingbing Jiang2, Ping Tsui3, Wen-Chao Song1

Poster No.

Conference Topic: Poster Browsing Conference 2

Conference Date and Time: August 28, 11:45-13:30 EST

Abstract and background: C3 glomerulopathy (C3G) is a rare kidney disease caused by dysregulation of alternative pathway activity in the complement system for which there is currently no effective treatment

1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, 2 Keyue Medicine, Suzhou, China, 3 Keyue Medicine, Cambridge, Massachusetts, USA

Statement: Dr.

About KP104

KP104 is the world's first bifunctional complement biopharmaceutical with a unique mechanism of action

Source: Kira Pharmaceuticals